Edition:
United States

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

62.49USD
4:00pm EDT
Change (% chg)

$-2.60 (-3.99%)
Prev Close
$65.09
Open
$65.32
Day's High
$65.92
Day's Low
$62.32
Volume
153,224
Avg. Vol
188,020
52-wk High
$70.93
52-wk Low
$26.56

Latest Key Developments (Source: Significant Developments)

Sage Therapeutics posts Q4 loss per share of $1.50
Thursday, 23 Feb 2017 06:30am EST 

Sage Therapeutics Inc : Sage Therapeutics announces fourth quarter and full year 2016 financial results and provides corporate update . Expects existing cash, cash equivalents, to fund anticipated level of operations, based on its current operating plans, into Q2' 18 .Qtrly loss per share $1.50.  Full Article

Sage-547 granted prime designation by EMA for treatment of postpartum depression
Wednesday, 16 Nov 2016 09:40am EST 

Sage Therapeutics Inc : Sage-547 granted prime designation by EMA for the treatment of postpartum depression .Company now anticipates globalizing its PPD development program and establishing european clinical operations.  Full Article

Sage Therapeutics announces third quarter 2016 financial results
Thursday, 3 Nov 2016 06:30am EDT 

Sage Therapeutics Inc : Sage Therapeutics Inc announces third quarter 2016 financial results and provides SRSE European update . Qtrly net loss per share $1.15 . Sage Therapeutics says ongoing phase 3 status trial expected to be sufficient to support european marketing authorization application for SAGE-547 in SRSE . Sage Therapeutics Inc says eight clinical trials across pipeline expected to generate top-line data in 2017 . Sage Therapeutics says expects existing cash, cash equivalents, marketable securities will fund operating and capital expenditure requirements into Q2 2018 .Sage Therapeutics says advancing a portfolio of multiple, novel central nervous system product candidates targeting GABA and NMDA receptor systems.  Full Article

Sage Therapeutics Q2 EPS ($1.08)
Tuesday, 9 Aug 2016 06:30am EDT 

Sage Therapeutics Inc : Sage Therapeutics announces second quarter 2016 financial results and provides corporate update .Qtrly loss per share $1.08.  Full Article

Sage Therapeutics says completed enrollment for Phase 2 trial of Sage-547
Thursday, 26 May 2016 04:05pm EDT 

Sage Therapeutics Inc :SAGE THERAPEUTICS announces completion of enrollment for phase 2 proof-of-concept trial of sage-547 in severe postpartum depression.  Full Article

Sage Therapeutics Announces Proposed Public Offering of Common Stock
Tuesday, 5 Jan 2016 04:09pm EST 

Sage Therapeutics, Inc:commenced an underwritten public offering of $150 million of its common stock.SAGE also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its common stock offered in the public offering.All of the shares in the offering are to be sold by SAGE.J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Leerink Partners LLC and Cowen and Company, LLC are serving as lead managers and Canaccord Genuity Inc. is serving as co-manager.  Full Article

SAGE Therapeutics announces positive top-line data in exploratory trial of SAGE-547 in Postpartum Depression
Tuesday, 9 Jun 2015 06:29am EDT 

SAGE Therapeutics Inc:Says marked improvement demonstrated in HAM-D scores in patients with ppd enrolled in open-label trial.Says plan to initiate placebo-controlled trial of sage-547 by year end.Says SAGE-547 was well-tolerated in patients treated with no serious adverse events.Says no serious adverse events were observed in patients on therapy or during the 30-day follow-up period.  Full Article

SAGE Therapeutics Inc announces closing of $138 mln public offering of common stock including full exercise of option to purchase additional shares
Tuesday, 21 Apr 2015 06:30am EDT 

SAGE Therapeutics Inc:Says closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 342,857 shares at the public offering price of $52.50 per share.Exercise of the option to purchase additional shares brought the total number of shares of common stock sold by SAGE to 2,628,571 shares and increased the amount of gross proceeds raised in the offering to about $138 mln.J.P. Morgan Securities LLC and Goldman, Sachs & Co. acted as joint book-running managers for the offering. Leerink Partners LLC and Cowen and Company, LLC served as co-managers.  Full Article

SAGE Therapeutics announces pricing of public offering of common stock
Tuesday, 14 Apr 2015 08:45pm EDT 

SAGE Therapeutics Inc:Prices an underwritten public offering of 2,285,714 shares of its common stock at a public offering price of $52.50 per share, before underwriting discounts.Grants the underwriters a 30-day option to purchase up to an additional 342,857 shares of common stock on the same terms and conditions.J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering.Leerink Partners LLC and Cowen and Company, LLC are serving as co-managers.Offering is expected to close on or about April 20.  Full Article

SAGE Therapeutics announces proposed public offering of common stock
Monday, 13 Apr 2015 04:28pm EDT 

SAGE Therapeutics:Commences an underwritten public offering of $100 million of shares of its common stock.Says all of the shares in the offering are to be sold by SAGE.Intends to grant the underwriters a 30-day option to purchase up to an additional $15 mln of shares of common stock at the public offering price, less the underwriting discount.J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering.Leerink Partners LLC and Cowen and Company, LLC are serving as co-managers.Offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.  Full Article

More From Around the Web

BRIEF-Sage Therapeutics posts Q4 loss per share of $1.50

* Sage Therapeutics announces fourth quarter and full year 2016 financial results and provides corporate update